Complete Guide to PRF Tubes: Biological Principles, Additive-Free Formulation & Clinical Use

Mariana Ruiz

Reading time: ~9 minutes | Target audience: Dentists, oral surgeons, aesthetic practitioners, regenerative medicine specialists
Last updated: Nov 12, 2026

Introduction

First introduced by Dr. Joseph Choukroun in 2001, Platelet-Rich Fibrin (PRF) represents the second generation of autologous platelet concentrates. While first-generation Platelet-Rich Plasma (PRP) relies on anticoagulants and synthetic separators to isolate liquid plasma, PRF adopts a purely biological approach: 100% natural, additive-free blood collection that allows autologous thrombin to polymerize fibrinogen slowly under controlled centrifugation.

The result is a three-dimensional, flexible fibrin matrix that traps viable platelets, leukocytes, and circulating mesenchymal stem cells. This architecture provides sustained, slow-release growth factor kinetics over 10 to 14 days, compared to the acute burst release (within hours) characteristic of PRP. This guide explores the biological mechanisms of PRF, the unique engineering of PRF tubes, and practical clinical considerations.

1. What Makes a PRF Tube Unique?

The fundamental distinction between a PRP tube and a PRF tube lies in what is—and what is not—inside:

  • Zero Anticoagulants: PRF tubes contain no ACD-A, sodium citrate, or heparin. Blood drawn into the tube immediately begins physiological clotting upon contact with the container walls.
  • Zero Separation Gel: Because the natural fibrin clot traps platelets and separates from red blood cells during low-speed centrifugation, artificial thixotropic gels are neither needed nor desired.
  • Additive-Free Sterility: True medical PRF tubes are 100% dry, sterile, and non-pyrogenic, manufactured in cleanroom environments to ISO 13485 medical device standards.

2. The Physiology of Fibrin Polymerization

2.1 Slow Physiological Polymerization vs. Rapid Chemical Activation

In standard PRP protocols, anticoagulant chemicals prevent clotting until the practitioner injects the material or introduces exogenous calcium chloride/bovine thrombin. This triggers an immediate, aggressive polymerization that forms rigid, brittle tetramolecular fibrin junctions, rapidly releasing growth factors within the first 60–90 minutes.

In contrast, PRF leverages the patient’s own endogenous thrombin concentrations. Under low-speed centrifugation, thrombin converts fibrinogen into fibrin monomer chains gradually, forming flexible, elastic trimolecular junctions. This delicate meshwork encapsulates intact platelets and immune cells without crushing or degranulating them prematurely.

2.2 The Cellular Composition of PRF

A well-prepared PRF clot comprises three vital components:

  • Equilateral Fibrin Mesh: An elastic biological scaffold that acts as a physical matrix for cell migration, capillary ingrowth, and extracellular matrix deposition.
  • Concentrated Platelets: Secreting PDGF, VEGF, TGF-β1, EGF, and IGF-1 continuously as the fibrin mesh naturally degrades over 7 to 14 days.
  • Leukocytes (Monocytes & Lymphocytes): Providing intrinsic immune defense, debridement phagocytosis, and anti-infective cytokine release at the surgical or treatment site.

3. Types of PRF Formats and Specialized Tubes

Depending on centrifugation parameters (RCF and spin time) and tube interior treatments, clinicians produce distinct clinical forms of PRF:

3.1 Solid PRF (L-PRF / A-PRF / Advanced PRF Clots & Membranes)

Collected in standard additive-free PRF tubes (typically medical PET or borosilicate glass), blood is spun at approximately 1,200–1,500 RPM for 12–14 minutes. The resulting jelly-like PRF fibrin clot is removed from the tube, separated from the red cell pellet with sterile scissors, and compressed in a surgical PRF box to form resilient PRF membranes or cut into plugs for dental socket preservation and bone graft augmentation.

3.2 Liquid PRF (i-PRF / Injectable PRF)

To produce an injectable liquid PRF before fibrin clogs the needle, clinicians use the Low-Speed Centrifugation Concept (LSCC)—spinning blood at lower speeds (e.g., 700 RPM, ~60 × g) for 3 to 4 minutes. In special smooth, hydrophobic PET tubes, clotting is delayed just long enough for the clinician to aspirate a liquid platelet-leukocyte-fibrinogen concentrate for facial aesthetic injection, hair follicle mesotherapy, or combining with bone particulates to form malleable "sticky bone."

4. Step-by-Step Clinical Handling: The Critical Time Factor

Because PRF tubes contain no anticoagulant, speed of venipuncture and centrifuge initiation is paramount:

  1. Rapid Blood Draw: Venipuncture should be completed in under 60–90 seconds per tube using a 21G or 22G butterfly needle set.
  2. Immediate Centrifugation: Tubes must be placed directly into the centrifuge rotor and spinning initiated within 60 to 90 seconds of blood draw. Delays cause blood to clot prematurely in the tube before cellular separation occurs, resulting in trapped platelets within the red cell fraction and a compromised yield.
  3. Careful Clot Harvesting: After the centrifuge cycle finishes, allow the rotor to come to a complete stop without braking. Gently grasp the glistening amber PRF clot with sterile tissue forceps and snip the dark erythrocyte boundary clean with surgical scissors.

5. Standard Diagnostic Red-Top Tubes vs. Certified PRF Tubes

Practitioners must avoid using standard red-top laboratory diagnostic tubes for PRF therapy:

  • Clot Activator Hazards: Many laboratory red-top tubes are spray-coated with microscopic silica particles or animal-derived thrombin to accelerate diagnostic clotting. Centrifuging and applying these synthetic particles to human surgical wounds or dermal tissue can cause severe foreign-body granulomas and chronic inflammatory reactions.
  • Sterilization Deficiencies: Diagnostic tubes are labeled for in vitro diagnostic use (IVD) only, lacking certified non-pyrogenicity and biocompatibility testing for surgical implantation.
  • Certified PRF Tubes: True PRF tubes are 100% additive-free, manufactured in ISO 13485 cleanroom facilities, and verified non-pyrogenic (<0.25 EU/ml) for autologous human tissue applications.

Summary

Platelet-Rich Fibrin represents a purely natural, autologous biomaterial that bridges biological cell therapy and tissue engineering. By utilizing certified additive-free PRF tubes and strictly controlling centrifuge timing, clinicians achieve dense, leukocyte-rich fibrin scaffolds that release therapeutic growth factors over prolonged regenerative windows.

To explore VivaPRP’s certified additive-free PRF collection tubes, visit our PRF Tubes Collection or view centrifuge protocols in our Complete PRF Tubes Guide.

Back to blog

Leave a comment